公开(公告)号：US20220127281A1

公开(公告)日：2022-04-28

申请号：US17449974

申请日：2021-10-05

申请人： AstraZeneca AB

发明人： Jason Grant KETTLE ,  Sharanjeet Kaur BAGAL ,  Scott BOYD ,  Andrew John EATHERTON ,  Shaun Michael FILLERY ,  Graeme Richard ROBB ,  Piotr Antoni RAUBO

IPC分类号： C07D498/14 ,  C07D519/00

摘要： The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

公开(公告)号：US20180280377A1

公开(公告)日：2018-10-04

申请号：US15772120

申请日：2016-11-02

申请人： ASTRAZENECA AB

发明人： Kurt Gordon PIKE ,  Bernard Christophe BARLAAM ,  Thomas Anthony HUNT ,  Andrew John EATHERTON

IPC分类号： A61K31/4745 ,  A61P35/04

摘要： The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1, R2, R3 and R4 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.

公开(公告)号：US20210221823A1

公开(公告)日：2021-07-22

申请号：US17053400

申请日：2019-05-07

申请人： AstraZeneca AB

发明人： Jason Grant KETTLE ,  Sharanjeet Kaur BAGAL ,  Andrew John EATHERTON ,  Shaun Michael FILLERY ,  Graeme Richard ROBB ,  Scott Gibson LAMONT ,  Paul David KEMMITT ,  Frederick Woolf GOLDBERG

IPC分类号： C07D498/14

摘要： The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

公开(公告)号：US20180318287A1

公开(公告)日：2018-11-08

申请号：US15772118

申请日：2016-11-02

申请人： ASTRAZENECA AB

发明人： Kurt Gordon PIKE ,  Bernard Christophe BARLAAM ,  Thomas Anthony HUNT ,  Andrew John EATHERTON

IPC分类号： A61K31/4745 ,  A61P35/00

CPC分类号： A61K31/4745 ,  A61K31/282 ,  A61K31/407 ,  A61K31/704 ,  A61K33/24 ,  A61K45/06 ,  A61K2121/00 ,  A61K2300/00 ,  A61P35/00 ,  C07D471/04

摘要： The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where x, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.